A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours

Trial Profile

A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Adavosertib (Primary) ; Caffeine; Granisetron; Midazolam; Omeprazole
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jun 2018 Planned End Date changed from 19 Jul 2018 to 22 Aug 2018.
    • 19 Jun 2018 Planned primary completion date changed from 19 Jul 2018 to 22 Aug 2018.
    • 19 Dec 2017 Planned End Date changed from 18 Jul 2018 to 19 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top